Cartoon Illustrating “The NIH and U.S. Healthcare in Crisis” Published
| | | | | | | | | | | | | | | | | | | | | | | | | |

Cartoon Illustrating “The NIH and U.S. Healthcare in Crisis” Published

On Apr. 21, 2025, LifeScienceHistory.com published the cartoon: “The National Institutes of Health (NIH) and U.S. Healthcare in…

75% of U.S. scientists who answered Nature poll consider leaving
| | | | | | | | | | | | | | | | | | |

75% of U.S. scientists who answered Nature poll consider leaving

On Mar. 27, 2025, a Nature survey of more than 1,200 scientists, three-quarters of the total respondents are…

Japan’s MHLW Approved CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
| | | |

Japan’s MHLW Approved CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

On Sept. 13, 2024, CSL Seqirus and sa-mRNA pioneer Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor…

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrated Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
| | | |

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrated Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

On Feb. 5, 2024, CSL and and Arcturus Therapeutics announced the results of a follow-up analysis of a…

CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
| | | |

CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…